Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Triple-negative Breast Carcinoma in African American and Caucasian Women Clinicopathology, Immunomarkers, and Outcome

Triple-negative Breast Carcinoma in African American and Caucasian Women Clinicopathology,... RESEARCH ARTICLE Triple-negative Breast Carcinoma in African American and Caucasian Women: Clinicopathology, Immunomarkers, and Outcome Harold C. Sullivan, MD,* Gabriela Oprea-Ilies, MD,* Amy L. Adams, MD,* Andrew J. Page, MD,w Sungjin Kim, MS,z Jason Wang, MD,* and Cynthia Cohen, MD* (Appl Immunohistochem Mol Morphol 2014;22:17–23) Purpose: Breast cancers are often classified on the presence/ab- sence of hormone receptors, and growth factor oncogenes (es- trogen receptor, progesterone receptor, HER2). Triple-negative breast cancers, negative for these markers, do not benefit from he term “breast cancer” includes a diverse group of targeted therapy. We compared clinicopathologic parameters Tcancers with varied clinical and biological character- and immunohistochemical markers of prognostic and/or pre- istics. Subtypes are regularly classified based on the dictive significance, and outcome between African American presence or absence of hormone receptors and growth and Caucasian triple-negative breast cancer patients. factor oncogenes, including estrogen receptor (ER), pro- gesterone receptor (PR), and human epidermal growth Methods: Invasive triple-negative breast cancers from African factor receptor 2 (HER2). Among the hormone-positive American (n = 94) and Caucasian (n = 68) patients were stud- breast cancers are the luminal (A and B) subtypes. Hor- ied. Clinicopathologic features (age, tumor size, grade, lymph mone receptor–negative breast cancers http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Triple-negative Breast Carcinoma in African American and Caucasian Women Clinicopathology, Immunomarkers, and Outcome

Loading next page...
 
/lp/wolters-kluwer-health/triple-negative-breast-carcinoma-in-african-american-and-caucasian-841IHn6GCp
Copyright
Copyright © 2013 by Lippincott Williams & Wilkins
ISSN
1541-2016
DOI
10.1097/PAI.0b013e318281148e
pmid
23455177
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Triple-negative Breast Carcinoma in African American and Caucasian Women: Clinicopathology, Immunomarkers, and Outcome Harold C. Sullivan, MD,* Gabriela Oprea-Ilies, MD,* Amy L. Adams, MD,* Andrew J. Page, MD,w Sungjin Kim, MS,z Jason Wang, MD,* and Cynthia Cohen, MD* (Appl Immunohistochem Mol Morphol 2014;22:17–23) Purpose: Breast cancers are often classified on the presence/ab- sence of hormone receptors, and growth factor oncogenes (es- trogen receptor, progesterone receptor, HER2). Triple-negative breast cancers, negative for these markers, do not benefit from he term “breast cancer” includes a diverse group of targeted therapy. We compared clinicopathologic parameters Tcancers with varied clinical and biological character- and immunohistochemical markers of prognostic and/or pre- istics. Subtypes are regularly classified based on the dictive significance, and outcome between African American presence or absence of hormone receptors and growth and Caucasian triple-negative breast cancer patients. factor oncogenes, including estrogen receptor (ER), pro- gesterone receptor (PR), and human epidermal growth Methods: Invasive triple-negative breast cancers from African factor receptor 2 (HER2). Among the hormone-positive American (n = 94) and Caucasian (n = 68) patients were stud- breast cancers are the luminal (A and B) subtypes. Hor- ied. Clinicopathologic features (age, tumor size, grade, lymph mone receptor–negative breast cancers

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Jan 1, 2014

There are no references for this article.